Hyderabad, India – Oct 2025 — Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad. This collaboration aims to bring high-value, next-generation sequencing (NGS) technologies closer to patients and healthcare providers across the country.
By combining AMPATH’s extensive diagnostic network with Gene Solutions’ expertise in genomics, the partnership will enable more timely, accessible, and informative testing in key areas such as reproductive health, cancer screening, and personalized medicine.
Bringing Advanced Genomics into Everyday Practice
AMPATH’s nationwide infrastructure—comprising over 20 satellite laboratories and more than 2,000 collection points—provides a strong foundation to introduce genomics into routine diagnostics. Leveraging this reach, the newly established NGS laboratory in Hyderabad will offer:
- triSure NIPT – A comprehensive non-invasive prenatal screening solution that provides insights into chromosomal conditions, microdeletions, and select single-gene disorders, supporting expectant parents with safe, early options for fetal health assessment and maternal well-being.
- SPOT-MAS – An innovative, clinically validated early cancer screening solution, designed to detect signals from 75 cancer types and subtypes using a single blood sample—providing physicians with additional tools to support early intervention.
- K-TRACK, K-4CARE – World-class cancer monitoring & genomic profiling solutions powered by multi-omics, enabling physicians to personalize treatment and monitor recurrence with greater confidence.
Supporting Better Patient Care Through Advanced Testing
The collaboration between Gene Solutions and AMPATH introduces advanced diagnostic tools that support more informed clinical decisions. By offering access to innovative genomic solutions, the partnership contributes to:
- Safer, more informative prenatal screening, empowering expectant parents with early, accurate insights into fetal health and maternal conditions.
- Earlier cancer detection, enabling physicians to identify signals from major cancers, including breast, lung, colorectal, and head & neck cancers, through a simple blood test.
- Personalized cancer care, helping oncologists tailor treatment and monitor recurrence through non-invasive genomic tools.
A Shared Vision for Accessible Precision Medicine
“This partnership reflects a shared vision—making high-quality, science-driven genetic testing more widely available,” said Dr. Nguyen Hoai Nghia, Co-founder and CEO of Gene Solutions. “We believe that technology should be inclusive. Working with AMPATH allows us to deliver advanced solutions through a familiar and trusted healthcare network.”
Dr. Maneesh Bagai, COO of AMPATH shared: “We are thrilled to expand into next-generation sequencing through this strategic alliance. Together, we are redefining what’s possible in diagnostics—whether it’s in maternal health, early cancer detection, or personalized oncology with patient centric approach.”
About AMPATH
AMPATH (American Institute of Pathology and Laboratory Sciences) is a trusted leader in pathology services in India, known for its adherence to international standards and excellence in clinical diagnostics. Headquartered in Hyderabad, AMPATH operates a Central Reference Laboratory and a growing network of 20+ satellite labs across India, supported by NABL (National Accreditation Board for Testing & Calibration Laboratories) accreditation.
AMPATH is part of CTSI South Asia, which also operates the American Oncology Institute (AOI) and a network of specialty hospitals, reinforcing its commitment to outcome-focused, patient-centric healthcare. Through this integrated ecosystem, AMPATH plays a pivotal role in supporting precision medicine, early disease detection, and personalized treatment strategies across oncology and other specialties.
